A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
A phase 3 trial testing HRS-8080 in HR-positive / HER2-negative breast cancer, now recruiting.
Overview
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer is a phase 3 interventional study registered as NCT07349069, led by Shandong Suncadia Medicine, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy. Planned enrolment is 5500 participants (estimated). The study started in 2026-03-04 and primary completion is expected in 2030-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.